Relaxin

Summary

Relaxin (CHEMBL2107882) is a phase-3 clinical-stage unknown targeting RXFP1, RXFP2, and RXFP3; indicated across 3 conditions including systemic sclerosis and congestive heart failure.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Targets: 3 (RXFP1, RXFP2, RXFP3)
• Indications: 3 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107882
Name	Relaxin
Type	Unknown
Max phase	3

Also known as: Pig relaxin, Porcine relaxin, Relaxin, Relaxin (swine), Relaxin porcine, Relaxin sus scrofa, RELAXIN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
RXFP1	RXFP1	Full agonist	10.37	0%	Q9HBX9
RXFP2	RXFP2	Full agonist	9.13	0%	Q8WXD0
RXFP3	RXFP3	Full agonist	10	0%	Q9NSD7

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 3 target gene(s): RXFP1, RXFP2, RXFP3.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Relaxin receptors	3	RXFP1, RXFP2, RXFP3
Signal Transduction	2	RXFP1, RXFP2
Signaling by GPCR	2	RXFP1, RXFP2
Class A/1 (Rhodopsin-like receptors)	2	RXFP1, RXFP2
Peptide ligand-binding receptors	2	RXFP1, RXFP2
GPCR downstream signalling	2	RXFP1, RXFP2
G alpha (s) signalling events	2	RXFP1, RXFP2
GPCR ligand binding	2	RXFP1, RXFP2
G alpha (i) signalling events	1	RXFP3

Dominant GO biological processes

GO term	Targets
signal transduction	3
G protein-coupled receptor signaling pathway	3
adenylate cyclase-activating G protein-coupled receptor signaling pathway	2
hormone-mediated signaling pathway	2
parturition	1
extracellular matrix organization	1
myofibroblast differentiation	1
lung connective tissue development	1
nipple morphogenesis	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
oocyte maturation	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
negative regulation of cell population proliferation	1
male gonad development	1
negative regulation of apoptotic process	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
systemic sclerosis	3	MONDO:0005100	EFO:0000717
congestive heart failure	2	MONDO:0005009	EFO:0000373
preeclampsia	1	MONDO:0005081	EFO:0000668

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	3
Not specified	3
PHASE2/PHASE3	1
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00520806	PHASE2/PHASE3	COMPLETED	Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
NCT00704665	PHASE3	COMPLETED	Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
NCT07359872	PHASE1/PHASE2	NOT_YET_RECRUITING	Relaxin Therapy for Atrial Fibrillation
NCT00004380	PHASE2	COMPLETED	Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
NCT00259116	PHASE2	COMPLETED	A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure
NCT03449251	PHASE2	UNKNOWN	A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
NCT06687486	Not specified	ACTIVE_NOT_RECRUITING	Effect of Autogenic Relaxation Therapy on Caregivers on Perceived Stress Quality of Life and Caregiver Burden
NCT06933602	Not specified	ACTIVE_NOT_RECRUITING	Progressive Relaxation for COPD: Effects on Insomnia and Satisfaction
NCT06808165	Not specified	COMPLETED	Relaxin and Placental Volume in Placenta Accreta Spectrum

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

11 molecules share ≥1 primary target. Top 11 by shared-target count:

Molecule	Source	Status	Shared targets
CLADRIBINE	ChEMBL	Phase 4 (approved)	RXFP1
EPINEPHRINE BITARTRATE	ChEMBL	Phase 4 (approved)	RXFP1
FAMCICLOVIR	ChEMBL	Phase 4 (approved)	RXFP1
ISOETHARINE	ChEMBL	Phase 4 (approved)	RXFP1
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	RXFP1
METHYSERGIDE	ChEMBL	Phase 4 (approved)	RXFP1
PENTOXIFYLLINE	ChEMBL	Phase 4 (approved)	RXFP1
SUPROFEN	ChEMBL	Phase 4 (approved)	RXFP1
COLFORSIN	ChEMBL	Phase 2	RXFP1
FLUBENDAZOLE	ChEMBL	Phase 2	RXFP1
LOMIFYLLINE	ChEMBL	Phase 2	RXFP1